膜杰作
Star Staining
抗体来源（Source）
Monoclonal Anti-C11D5.3 scFv Antibody, Mouse IgG1 (3G8C1) is a Mouse monoclonal antibody recombinantly expressed from HEK293 cells.
克隆号（Clone）
3G8C1
种属（Species）
Mouse
亚型（Isotype）
Mouse IgG1 | Mouse kappa
抗体类型（Antibody Type）
Recombinant Monoclonal
种属反应性（Reactivity）
Mouse
免疫原（Immunogen）
Recombinant Mouse C11D5.3 scFv derived from HEK293 cells.
特异性（Specificity）
Specifically recognizes the antigen-recognition domain of C11D5.3 derived CARs.
应用（Application）
| Application | Recommended Usage |
| ELISA | 0.2-250 ng/mL |
纯度（Purity）
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
纯化（Purification）
Protein A purified / Protein G purified
制剂（Formulation）
Supplied as 0.2 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
运输（Shipping）
This product is supplied and shipped with dry ice, please inquire the shipping cost.
存储（Storage）
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- The product MUST be stored at -70°C or lower upon receipt;
- -70°C for 3 months under sterile conditions.
电泳（SDS-PAGE）
Monoclonal Anti-C11D5.3 scFv Antibody, Mouse IgG1 (3G8C1) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
SEC-MALS
The purity of Monoclonal Anti-C11D5.3 scFv Antibody, Mouse IgG1 (3G8C1) (Cat. No. C13-MY2010b) is more than 90% and the molecular weight of this protein is around 135-165 kDa verified by SEC-MALS.
Report
活性（Bioactivity）-ELISA
Immobilized Mouse anti-BCMA scFv (C11D5.3), His Tag at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-C11D5.3 scFv Antibody, Mouse IgG1 (3G8C1) (Cat. No. C13-MY2010b) with a linear range of 0.2-8 ng/mL (QC tested).
Protocol
背景（Background）
C11D5.3 is an IgG1 mouse monoclonal antibody specific for BCMA, which is a target for the immunotherapy of multiple myeloma and lymphomas. C11D5.3 scFv is the most commonly used ectodomain componse of BCMA-specific CARs. So far, multiple reported CART BCMA trials contain the anti-BCMA scFv derived from C11D5.3, such as FDA approved CARs Abecma.
